


UNIVERSIDADE FEDERAL DO PARANÁ

FRANCIELLI AMBROSINI

AVALIAÇÃO DO SEIO CORONÁRIO COMO MEDIDA AUXILIAR NO  
DIAGNÓSTICO DA HIPERTENSÃO PULMONAR EM CÃES.

CURITIBA  
2022



FRANCIELLI AMBROSINI

AVALIAÇÃO DO SEIO CORONÁRIO COMO MEDIDA AUXILIAR NO  
DIAGNÓSTICO DA HIPERTENSÃO PULMONAR EM CÃES.

Dissertação apresentada ao Programa de Pós-Graduação em Ciências Veterinárias, do Setor de Ciências Agrárias, Universidade Federal do Paraná, como requisito parcial à obtenção do título de Mestre em Ciências Veterinárias.

Orientador: Prof. Dr. Marlos Gonçalves Sousa

CURITIBA  
2022

DADOS INTERNACIONAIS DE CATALOGAÇÃO NA PUBLICAÇÃO (CIP)  
UNIVERSIDADE FEDERAL DO PARANÁ  
SISTEMA DE BIBLIOTECAS – BIBLIOTECA DE CIÊNCIAS AGRÁRIAS

Ambrosini, Francieli

Avaliação do seio coronário como medida auxiliar no diagnóstico da hipertensão pulmonar em cães / Francieli Ambrosini . – Curitiba, 2022.

1 recurso online: PDF.

Dissertação (Mestrado) – Universidade Federal do Paraná, Setor de Ciências Agrárias, Programa de Pós-Graduação em Ciências Veterinárias.

Orientador: Prof. Dr. Marlos Gonçalves Sousa

1. Hipertensão pulmonar. 2. Cães. I. Sousa, Marlos Gonçalves. II. Universidade Federal do Paraná. Programa de Pós-Graduação em Ciências Veterinárias. III. Título.

Bibliotecária: Telma Terezinha Stresser de Assis CRB-9/944



MINISTÉRIO DA EDUCAÇÃO  
SETOR DE CIÊNCIAS AGRÁRIAS  
UNIVERSIDADE FEDERAL DO PARANÁ  
PRÓ-REITORIA DE PESQUISA E PÓS-GRADUAÇÃO  
PROGRAMA DE PÓS-GRADUAÇÃO CIÊNCIAS  
VETERINÁRIAS - 40001016023P3

## TERMO DE APROVAÇÃO

Os membros da Banca Examinadora designada pelo Colegiado do Programa de Pós-Graduação CIÊNCIAS VETERINÁRIAS da Universidade Federal do Paraná foram convocados para realizar a arguição da dissertação de Mestrado de **FRANCIELLI AMBROSINI** intitulada: **AVALIAÇÃO DO SEIO CORONARIANO COMO MEDIDA AUXILIAR NO DIAGNÓSTICO DE HIPERTENSÃO PULMONAR EM CÃES**, sob orientação do Prof. Dr. MARLOS GONÇALVES SOUSA, que após terem inquirido a aluna e realizada a avaliação do trabalho, são de parecer pela sua APROVAÇÃO no rito de defesa.

A outorga do título de mestra está sujeita à homologação pelo colegiado, ao atendimento de todas as indicações e correções solicitadas pela banca e ao pleno atendimento das demandas regimentais do Programa de Pós-Graduação.

CURITIBA, 31 de Janeiro de 2022.

Assinatura Eletrônica

11/02/2022 19:31:04.0

MARLOS GONÇALVES SOUSA

Presidente da Banca Examinadora

Assinatura Eletrônica

11/02/2022 18:44:19.0 TATIANA CHAMPION

Avaliador Externo (UNIVERSIDADE FEDERAL DA FRONTEIRA SUL)

Assinatura Eletrônica

14/02/2022 15:51:35.0

SIMONE TOSTES DE OLIVEIRA STEDILE

Avaliador Interno (UNIVERSIDADE FEDERAL DO PARANÁ)

---

RUA DOS FUNCIONÁRIOS, 1540 - CURITIBA - Paraná – Brasil  
CEP 80035050 - Tel: (41) 3350-5621 - E-mail: cpgcv@ufpr.br  
Documento assinado eletronicamente de acordo com o disposto na legislação federal Decreto 8539 de 08 de outubro de 2015.

Gerado e autenticado pelo SIGA-UFPR, com a seguinte identificação única: 148269

**Para autenticar este documento/assinatura, acesse**  
**<https://www.prppg.ufpr.br/siga/visitante/autenticacaoassinaturas.jsp>**  
**e insira o código 148269**

Aos meus amados filhos Millena e Emmanuel.

Ao meu grande e eterno amor Ivanio.

## RESUMO

Introdução/objetivos: a síndrome da hipertensão pulmonar é caracterizada por um aumento sustentado da pressão na vasculatura pulmonar. O diagnóstico padrão-ouro é feito com cateterismo cardíaco, mas a ecocardiografia destina-se a realizar a abordagem probabilística. O seio coronário (SC) é uma estrutura vascular que aumenta com o aumento da pressão no átrio direito, pressão na artéria pulmonar e está relacionado com o prognóstico da hipertensão pulmonar (HP). Este estudo visa validar o uso desta medida em cães, como parâmetro complementar ao diagnóstico desta condição. Animais: foi realizada avaliação ecocardiográfica de 61 cães, subdivididos em grupos de acordo com a probabilidade de HP. Materiais e métodos: estudo observacional analítico e transversal. As medidas ecocardiográficas padrão foram registradas pelo mesmo avaliador na janela paraesternal esquerda e direita. O seio coronariano foi medido no início do QRS e ao final da onda t do eletrocardiograma, em triplicata, e em seguida a respectiva média foi indexada pelo peso, raiz cúbica do peso, diâmetro da aorta e área de superfície corporal. O SC foi comparado com TAPSE, FAC, RPA, AT/ET, AP/AO. Resultados: As médias indexadas ou não foram maiores em PH<sub>h</sub> comparado a PH<sub>i</sub> e PH<sub>l</sub> ( $p < 0,01$ ), mas não diferiram do grupo controle. A medida de SC aumenta progressivamente de acordo com a probabilidade de HP. As curvas ROC para identificação de pacientes com HP apresentaram  $AUC > 0,7$  para a média de todas as indexações do SC.  $CS_{Q\text{RSAo}}$ ,  $CS_{\text{TB}}$ ,  $CS_{\text{TAo}}$ ,  $CS_{\text{QRSR}}$ ,  $CS_{\text{TW}}$  apresentaram correlação positiva com insuficiência tricúspide ( $RHO > 0,6$  e  $p < 0,001$ ). Na análise de sobrevida,  $CS_{\text{TW}}$ ,  $CS_{\text{QRSB}}$ ,  $CS_{\text{TB}}$ ,  $CS_{\text{QRSW}}$ ,  $CS_{\text{TAo}}$ ,  $CS_{\text{QRSR}}$ ,  $aCS_{\text{T}}$ ,  $CS_{\text{Q\text{RSAo}}}$ ,  $aCS_{\text{QRS}}$ ,  $CS_{\text{TR}}$  apresentaram valores satisfatórios de sensibilidade e especificidade ( $AUC > 0,7$ ), e até melhores comparado aos outros índices ecocardiográficos. O coeficiente de correlação intraclasse apresentou resultados  $> 0,9$  tanto na avaliação intra quanto interobservador. Conclusões: O SC sofre dilatação na HP. Foi adequado para o

diagnóstico de pacientes com HP, mas não mostrou diferença nos pacientes do grupo controle. O uso do diâmetro SC é recomendado para a abordagem ecocardiográfica probabilística da HP quando indexado, especialmente pela área de superfície corporal e/ou diâmetro da aorta e é considerado um bom indicador prognóstico para HP.

Palavras-chave: pressão átrio direito, dilatação seio coronário; regurgitação tricúspide; probabilidade de hipertensão pulmonar; artéria pulmonar.

## ABSTRACT

**Introduction/objectives:** Pulmonary hypertension syndrome is augmented by a sustained increase in vasculature. The gold standard diagnosis is made with cardiac catheterization, but echocardiography is intended to perform the probabilistic approach. Coronary sinus (CS) is an enlarged vascular structure with increasing pressure that is not right pulmonary artery pressure and is related to the prognosis of pulmonary hypertension (PH). This study aims to validate the use of this measure in dogs, as a complementary parameter to the diagnosis of this condition. **Animals:** an echocardiographic evaluation was performed on 61 dogs, subdivided into groups according to the probability of PH. **Materials and methods:** analytical and cross-sectional observational study. Standard echocardiographic measurements were recorded by the same evaluator in the left and right parasternal window. The coronary sinus was measured at the beginning of the QRS and at the end of the electrocardiogram waveform, respectively, and then the mean cubic was indexed by weight, cube root weight, aortic diameter and body surface area. SC was compared with TAPSE, FAC, RPAD, AT/ET, AP/AO. **Results:** Means indexed or not were higher in PHh compared to Phi and PHI ( $p < 0.01$ ), but did not differ from the control group. SC measurement increases according to the possibility of PH. The ROC curves for identifying patients with PH showed  $AUC > 0.7$  for the mean of all SC indexes. CSQRSA, CSTB, CSTAO, CSQRSR, CSTW apparently positive with tricuspid function ( $RHO > 0.6$  and  $p < 0.001$ ). In the lifetime analysis, CSTw, CSQRSB, CSTB, CSQRSW, CSTAo, over CSQRSR, CSQRSAo, overQRS, CSTR, patterns, sensitivity and specificity values ( $AUC > 0.7$ ), and even better compared to echocardiographic indices. Both intraclass evaluation results presented  $> 0.9$  in intra and interobserver. **Conclusions:** SC undergoes dilation in HP. It was adequate for the diagnosis of patients with PH, but showed no difference in patients in the control group. The use of SC diameter is recommended for the probabilistic echocardiographic approach to PH when indexed, especially by body surface area and/or aortic diameter, and is considered a good prognostic indicator for PH. **Keywords:** right vertical pressure; coronary sinus dilatation; tricuspid regurgitation; probability of pulmonary hypertension; pulmonary.



## LIST OF ILLUSTRATIONS

- Figure 1** - Modified apical 4-chamber images used to measure the coronary sinus at the beginning of the QRS complex (A) and at the end of the T wave (B) ..... 25
- Figure 2** - Survival analysis of dogs with varying degrees of PH according to measurement of CS.....26
- Figure 3** - Survival analysis of dogs with varying degrees of PH according to echocardiographics variables. FAC: fractional area change.....27

## LIST OF TABLES

<b>Table 1</b> - Echocardiographic variables used to evaluate the probability of PH in dogs. Data are presented as either mean±SD or median (IQR).....	28
<b>Table 2</b> - Measurements of the CS obtained at end-systole (end of the T wave) and end-diastole (beginning of the QRS complex) in healthy dogs and dogs with PH. Data are presented as either mean±SD or median (IQR).....	29
<b>Table 3</b> - Correlations between echocardiographic variables and tricuspid regurgitation peak velocity.....	30
<b>Table 4</b> - Cut-off points, sensitivity and specificity of several echocardiographic variables used for identifying dogs with intermediate or high probability of PH .....	31-32
<b>Table 5</b> - Cut-off points for echocardiographic variables with better specificity and sensitivity values to predict deaths from PH .....	33-34

## LIST OF ABBREVIATIONS

AT	Pulmonary Flow Acceleration Time
AT/ET	Pulmonary flow acceleration-to ejection time ratio
BSA	Body surface area
CS	Coronary Sinus
$aCS_{QRS}$	Average of CS measured at the beginning of the QRS complex
$CS_{QRSaO}$	$CS_{QRS}$ aorta-indexed
$CS_{QRSB}$	$CS_{QRS}$ body surface area-indexed
$CS_{QRSR}$	$CS_{QRS}$ root-indexed
$CS_{QRSW}$	$CS_{QRS}$ weight-indexed
$aCS_T$	Average of CS measured at the end of the T wave
$CS_{TAo}$	$CS_T$ aorta-indexed
$CS_{TB}$	$CS_T$ body surface area-indexed
$CS_{TR}$	$CS_T$ root-indexed
$CS_{TW}$	$CS_T$ weight-indexed
E	Specificity
ET	Pulmonary Artery Ejection Time
FAC	Fractional Area Change
PH	Pulmonary Hypertension
$PH_l$	Low PH probability
$PH_h$	High PH probability
$PH_i$	Intermediate PH probability
S	Sensitivity
TAPSE	Tricuspid Annular Plane Systolic Excursion
TR PV	tricuspid regurgitation peak velocity
TR PG	tricuspid regurgitation pressure gradient

## SUMMARY

<b>1. INTRODUCTION .....</b>	<b>11-12</b>
<b>2. ANIMALS, MATERIALS AND METHODS .....</b>	<b>12</b>
2.1. Classification by probability of PH .....	13
2.2. Coronary sinus measurement.....	13
2.3. Pulmonary artery assessment.....	13
2.4. Left ventricular assessment .....	14
2.5. Right ventricular assessment.....	14
<b>3. STATISTICAL ANALYSIS.....</b>	<b>14-16</b>
<b>4. RESULTS .....</b>	<b>16-18</b>
<b>5. DISCUSSION.....</b>	<b>18-20</b>
<b>6. LIMITATIONS .....</b>	<b>20-21</b>
<b>7. CONCLUSIONS .....</b>	<b>21</b>
<b>8. REFERENCES .....</b>	<b>22-24</b>
<b>9. FIGURES .....</b>	<b>25-27</b>
<b>10. TABLES.....</b>	<b>28-34</b>

## 1 INTRODUCTION

2 Pulmonary hypertension (PH) is a multifactorial condition resulting from the  
3 imbalance of endogenous and exogenous vasodilator and vasoconstrictor factors  
4 acting in the pulmonary artery and resulting increase of pressure [17]. In people,  
5 pulmonary hypertension is characterized by an increase in either pulmonary systolic  
6 pressure above 25 mmHg or diastolic blood pressure above 19 mmHg [6], criteria  
7 also used in dogs. Its origin may be related to disturbances in the precapillary  
8 (arterial) or postcapillary (venous) vascular resistance of the pulmonary vascular  
9 system [11, 12].

10 In spite of the advanced diagnostic techniques available nowadays, cardiac  
11 catheterization remains the gold standard for measurement of systolic, mean and  
12 diastolic pulmonary artery pressure [5,19]. However, the echocardiogram is the  
13 indirect method most used in dogs for PH diagnostic. With that technique, tricuspid  
14 regurgitation peak velocity is used to estimate pulmonary artery systolic pressure,  
15 which is interpreted together with other echocardiographic signs of remodeling in  
16 the pulmonary artery, ventricles, right atrium and caudal vena cava, to establish the  
17 probability of having PH [11, 19].

18 Nonetheless, the use of tricuspid regurgitation peak gradient as a substitute  
19 for invasive pulmonary artery pressure measurement is subject to flaws for both  
20 diagnosis and classification [2, 20, 10]. Evaluation by echocardiography can lead to  
21 underdiagnosis of PH or incorrect classification of PH severity in many canine  
22 patients, especially in acute cases. Therefore, other echocardiographic surrogates  
23 for the existence and severity of PH are warranted [18].

24 The coronary sinus (CS) is a venous structure that lies in the posterior  
25 sulcus between the left atrium and left ventricle. Drains the veins of the myocardium  
26 and opens in the right atrium. An increase in its diameter can be used as an  
27 indication of increased pressure in the right atrium [1]. In human beings, CS  
28 diameter was positively correlated with pulmonary artery systolic pressure [8] and is

29 related to prognosis of PH [3]. To the best of our knowledge, the role played by PH  
30 in the characteristics of CS anatomy has not been investigated in dogs. Since PH is  
31 associated with increased right atrium pressure, we hypothesized that PH would  
32 change the diameter of the CS [18; 26). Thus, the aims of this study were three-fold:  
33 (1) to evaluate the anatomy of the CS using echocardiography in dogs with PH; (2)  
34 to assess whether changes in CS anatomy might predict the probability of a dog  
35 having PH; and (3) to assess the prognostic applicability of such measurements in  
36 comparison with other surrogates for right ventricular function.

37

### 38 **ANIMALS, MATERIALS AND METHODS**

39 This is a cross-sectional analytical observational study, carried out at a  
40 Veterinary Teaching facility between January 2021 and September 2021. Client-  
41 owned-dogs attending a referral practice with diagnosis of low, intermediate and  
42 high probability of PH, regardless of age, breed and weight, were included in the  
43 study. Also, healthy dogs were recruited to serve as controls. Data were collected  
44 regarding the use of medications, probable identification of the origin of PH (pre-  
45 or post-capillary) and history of decompensation of heart failure. Echocardiographic  
46 assessments were performed using an ultrasound equipment equipped with 2-12  
47 MHZ multifrequency transducers (Affiniti 50, Philips). No sedation was used. The  
48 animals were restrained in right and left lateral decubitus as recommended by the  
49 American College of Veterinary Internal Medicine [24]. All measurements were  
50 obtained by the same operator (FA). Exclusion criteria included animals with overt  
51 signs of congestive heart failure, labored breathing, congenital heart disease, RV  
52 outflow tract obstruction, intracardiac tumor or uncooperative animals unable to  
53 tolerate the exam. This study was approved by the institutional animal ethics  
54 committee under protocol number 027/2020.

55

## 56 Classification by probability of PH

57 To classify the probability of PH, tricuspid regurgitant flow was measured  
58 and the pressure gradient between right ventricle and right atrium was calculated  
59 using the modified Bernoulli equation. For the analysis of tricuspid regurgitation, a  
60 clearly visible envelope was considered, with dense marking of the envelope and  
61 a good quality signal. Also, anatomical sites at which alterations are likely to be  
62 documented were evaluated (ventricles, pulmonary artery, right atrium and caudal  
63 vena cava). These findings were used to establish the probability of animals having  
64 PH as low PH (PH<sub>l</sub>), intermediate (PH<sub>i</sub>), or high (PH<sub>h</sub>), as recommended as  
65 recommended by the American College of Veterinary Internal Medicine [19]. Of  
66 note, patients which did not present echocardiographic evidence, i.e. those which  
67 were unlikely to have PH, were used as controls.

68

## 69 Coronary sinus measurement

70 The CS is located in the left atrioventricular groove. From the left parasternal  
71 window, modified apical four-chamber images were recorded (i.e. with a slight  
72 cranial tilt of the transducer). Triplicate measurements of the CS diameter were  
73 obtained at the beginning of the QRS complex (CS<sub>QRS</sub>) and at the end of the T wave  
74 (CS<sub>T</sub>) (Fig. 1A and 1B, respectively).

75

## 76 Pulmonary artery assessment

77 From the right parasternal window, short-axis images of the heart base were  
78 obtained to show the pulmonary artery bifurcation. Measurements included  
79 pulmonary artery diameter, pulmonary artery-to-aorta ratio (PA/Ao), ejection and  
80 acceleration time of the pulmonary flow, as well as the ratio of these values (AT/ET).  
81 Lastly, we calculated the right pulmonary artery distensibility (maximum systolic  
82 inner diameter – minimum diastolic inner diameter/maximum systolic inner diameter  
83 \* 100).

84

85 Left ventricular assessment

86 Using either apical 4- or 5-chamber images, we recorded the isovolumic  
 87 relaxation time and ratio between mitral E wave (rapid ventricular filling) and A  
 88 wave (atrial contraction), E wave deceleration time (EDT). All Doppler assessments  
 89 were interrogated with the best alignment to avoid underestimation.

90

91 Right ventricular assessment

92 Modified apical 4-chamber images optimized for the RV were used to  
 93 measure tricuspid annular plane systolic excursion (TAPSE), and the fractional area  
 94 change (FAC).

95

## 96 **STATISTICAL ANALYSIS**

97 Descriptive analyses of the data were performed with an estimate of mean,  
 98 median, standard deviation, 25% and 75% percentiles of the quantitative variables  
 99 and simple and relative frequencies of the qualitative variables. Also,  $CS_T$  and  
 100  $CS_{QRS}$  measurements were normalized using four different indices: 1) body weight  
 101 (BW) ( $CS_{TW}$  and  $CS_{QRSW}$ ) [mm/kg]; 2) the cubic root of the BW ( $CS_{TR}$  and  $CS_{QRSR}$ )  
 102 [in  $\text{mm}/\sqrt[3]{\text{kg}}$ ]; 3) the diameter of the aorta ( $CS_{TA0}$  and  $CS_{QRSa0}$ ); and 4) the body  
 103 surface area ( $CS_{TB}$  and  $CS_{QRSB}$ ) [ $\text{mm}/\text{m}^2$ ], which was obtained through the following  
 104 formula:  $BSA = K \times (BW \text{ in grams})^{\frac{2}{3}} \times 10^{-4}$

105  $K = \text{constant (10.1 for dogs)}$

106 All data underwent the Shapiro-Wilk normality test. To investigate the  
 107 statistical difference of variables between controls and PH groups ( $PH_i$ ,  $PH_h$ ,  
 108 an ANOVA test followed by the post-hoc Tukey test was used whenever data was



109 normally distributed. For data that did not attain a gaussian distribution we used the  
110 Kruskal Wallis test followed by Dunn's test to compare groups.

111 Pearson's or Spearman's correlation coefficient was used to investigate the  
112 correlation between echocardiographic variables and  $CS_T$  and  $CS_{QRS}$ . To interpret  
113 the relevance of the correlation, the following classification was adopted: correlation  
114 coefficients  $<0.3$  (poor),  $0.3$  and  $0.5$  (fair),  $0.6$  and  $0.8$  (moderately strong) and  $> 0.8$   
115 (very strong) [4].

116 To verify which indexes best identified dogs with either  $PH_i$  or  $PH_h$ , the dogs  
117 of the study were divided into two groups: high/intermediate probability and low  
118 probability/controls. Then, the best cutoff point for CS measurements to identify  
119 dogs with  $PH_i$  or  $PH_h$  was determined by constructing the ROC curves and  
120 calculating the area under the curve (AUC).  $AUC > 0.7$  was considered adequate  
121 [13].

122 Kaplan-Meier curves were used to investigate the prognostic applicability of  
123 echocardiographic indices and CS measures, with mortality as the final outcome.  
124 Also, we analyzed the survival of patients according to the presence/absence of  
125 overt clinical signs, as well as the probability of PH.

126 To calculate intra-observer and inter-observer coefficients of variation,  
127 echocardiographic images obtained in 10% of patients enrolled in this investigation  
128 were randomly selected for repeat measurements of  $CS_T$  and  $CS_{QRS}$  by both the  
129 same observer (FA) and a second investigator blinded to the results (BCPV).  
130 Repeat measures were compared with intraclass correlation coefficient. Values less  
131 than  $0,5$  are indicative of poor reliability, values between  $05$  and  $0,75$  indicate  
132 moderate reliability, values between  $0.75$  and  $0.9$  indicate good reliability, and  
133 values greater than  $0.90$  indicate excellent reliability [13].

134 All analyzes were performed using Graphpad Prism software version 9.0®  
135 and tests were considered significant when  $p < 0.05$ .

136

137 **RESULTS**

138 This study included 61 dogs (34 males; 27 females; 4-5 years (n=3); 6-11  
139 years (n=30); and 12-17 years (n=28) met the inclusion criteria. Of these, 38 dogs  
140 (62,3 %) were diagnosed with PH, with 28 (73,7%), 7 (18,4%) and 3 (7,9%) of them  
141 considered to be either pre-capillary, post-capillary or mixed in origin, respectively.  
142 Also, the probability of having PH was determined to be low (PH<sub>l</sub>) in 15 dogs  
143 (24,5%), intermediate (PH<sub>i</sub>) in 11 (18,03%), and high (PH<sub>h</sub>) in 12 (19,7 %). Of note,  
144 23 dogs were recruited to serve as controls, i.e. were not considered as having PH  
145 based criteria described elsewhere [19]. Several breeds were represented in the  
146 study, including Airedale Terrier, Beagle, Boxer, French Bulldog, Bull Terrier,  
147 Chihuahua, Cocker Spaniel, Great Dane, Fila Brasileiro, Fox Terrier, Pekingese,  
148 Miniature Poodle, Spitz (one each), Dachshund, Standard Poodle, Schnauzer (two  
149 each), Labrador Retriever, Lhasa Apso (three each), Pinscher (n=6), Shih Tzu  
150 (n=9), and mixed breed dogs (n=20). While control dogs had a mean age of 9.2  
151 years, PH dogs had a mean age of 12 years (PH<sub>l</sub> 10.8 years; PH<sub>i</sub> 11.6 years; PH<sub>h</sub>  
152 13.5 years).

153 While none of the animals in the control group were on medications, 19  
154 (50%) PH dogs were treated. Of the dogs with PH<sub>l</sub> 13.3% received pimobendan,  
155 6.7% were on furosemide and enalapril and 6,7% combination of salmeterol  
156 xinafoate and fluticasone propionate. For dogs with PH<sub>i</sub>, 45,5% were taking  
157 medications, including sildenafil (9,1%), combination of salmeterol and fluticasone  
158 propionate (9,1%), enalapril (18,2%), and furosemide and pimobendan (18,2%).  
159 Lastly, 83.3% of dogs with PH<sub>h</sub> were medicated. While pimobendan associated  
160 with at least two diuretics was used in 41.7% of that population, sildenafil was used  
161 either alone (25%) or associated with diuretics (16,7%).

162 Table 1 present the echocardiographic variables used to assess the  
163 probability of PH in dogs. Post hoc multiple comparison tests identified differences

164 between PH categories. Tricuspid regurgitation velocity and gradient were higher  
165 in animals with PH<sub>h</sub> as compared to dogs with PH<sub>l</sub> and PH<sub>i</sub>. Also, PA/Ao ratio was  
166 higher in PH<sub>h</sub> dogs when compared to PH<sub>l</sub> and PH<sub>i</sub>. The diameter of  $aCS_T$ ,  $CS_{TW}$ ,  
167  $CS_{TR}$ ,  $CS_{TB}$ ,  $aCS_{QRS}$ ,  $CS_{QRSW}$ ,  $CS_{QRSR}$  and  $CS_{QRSB}$ . The measure of  $CS_{TAo}$  and  
168  $CS_{QRSAo}$  were lower as the probability of PH increased, as they are inversely  
169 proportional (Table 2). As the probability of PH increases, the diameter of the CS  
170 increases accordingly.

171  $CS_{QRSB}$ ,  $CS_{TB}$ ,  $CS_{QRSR}$ ,  $CS_{TW}$ ,  $CS_{TR}$  and AP/Ao showed a moderate to  
172 strong positive correlation with tricuspid regurgitation peak velocity (Table 3).  $CS_{TAo}$   
173 and  $CS_{QRSAo}$  had a moderate to strong negative correlation with tricuspid  
174 regurgitation peak velocity. Interestingly, in most cases correlations were better  
175 than that obtained between tricuspid regurgitation peak velocity and standard  
176 echocardiographic parameters used as criteria to assess the probability of PH in  
177 dogs.

178 ROC curves were constructed to assess cut-offs, sensitivity and specificity  
179 of echocardiographic variables to identify dogs with the more advanced forms of  
180 PH (i.e., PH<sub>l</sub> and PH<sub>h</sub>). AUC >0.7 were documented for tricuspid regurgitation peak  
181 velocity, tricuspid regurgitation pressure gradient, PA/Ao, as well as all  
182 measurements related to CS width (Table 4). ROC curves were also used to  
183 assess how several echocardiographic variables perform to predict mortality. The  
184 highest AUC (>0.8) were documented for tricuspid regurgitation peak velocity,  
185  $CS_{QRSW}$ ,  $CS_{QRSAo}$ ,  $CS_{TAo}$ , and PA/Ao (Table 5). In addition, the measurements of  
186  $CS_{QRSB}$ ,  $CS_{TB}$ ,  $CS_{TW}$ ,  $CS_{TR}$ ,  $CS_{QRSR}$ , had AUC>0.7, and were considered  
187 adequate.

188 Figure 2 and Figure 3 present the analysis of survival of patients with PH  
189 according to the cut-off points of EC measurements and other echocardiographic  
190 variables used as criteria for identifying PH, respectively. Patients with  $CS_{TAo}$ <5,  
191  $CS_{QRSAo}$ <6 had a median survival of 180 days. Those with  $CS_{QRSW}$  > 0.034 or TR

192 PV > 306 had a median survival of 150 days. It was not possible to calculate  
193 survival time.

194 The intraclass correlation coefficient was >0.9 in all analysis, both  
195 intraobserver and interobserver assessment of the  $aCS_T$  and  $aCS_{QRS}$   
196 measurements.

197197

## 198 **DISCUSSION**

199199

200 As far as these authors know, this is the first study evaluating how the CS  
201 diameter changes in dogs with PH, as well as its correlation with echocardiographic  
202 markers of PH. The CS measurement proved to be easy to acquire and exhibited  
203 excellent repeatability and reproducibility. Nonetheless, since several breeds were  
204 enrolled in this study, having CS measurements normalized to body size was  
205 necessary to compare different populations. Although several indexes were  
206 effective and showed good results, we recommend the use of body surface area  
207 and aortic diameter as standard indexes.

208 Although easily visualized, the CS has been traditionally ignored in the  
209 standard echocardiographic evaluation of animals. Interestingly, at least in people  
210 dilation of the coronary sinus has been recognized as an index of heart failure  
211 severity [27]. A study in people undergoing cardiac catheterization documented a  
212 positive correlation between CS diameter and right atrial pressure [15]. This finding  
213 might represent an advantage of CS measurements since methods intended to  
214 estimate right atrial pressure using the tricuspid regurgitation pressure gradient are  
215 neither validated for dogs not recommended [21, 22]. In our study, dogs with the  
216 higher probability of PH presented wider CS dimensions, similar to what has been  
217 reported in people [3]. Such finding is ascribed to the elevated pulmonary artery  
218 systolic pressure [14, 6] which eventually causes the elevation of right atrial  
219 pressure [1]. Also, dilation of the CS was demonstrated by computed tomography  
220 in humans with increased pulmonary artery pressure [9], whereas another

221 investigation demonstrated a significant correlation between the dilated CS and  
222 pulmonary artery systolic pressure, right atrial pressure, right heart chamber  
223 volumes, right ventricular ejection fraction and inferior vena cava [8]. Cetin et al  
224 (2015) [3] demonstrated that people with LV of normal size and function had an  
225 increased CS diameter when they had moderate and severe PH and it was  
226 correlated with pulmonary artery systolic pressure and right atrial pressure. This  
227 study was able to detect CS dilatation in patients with low, intermediate and high  
228 PH. This suggests that it may be an early indicator for PH, even in those cases  
229 where severe remodeling has not yet occurred. As there was no difference in the  
230 control group compared to the other groups, it can be said that this measure is safe  
231 for the diagnosis only of those affected by the disease. It is possible that there is a  
232 difference in this dilation when comparing patients with pre and post capillary PH,  
233 and this can be further investigated in future studies.

234 Tricuspid regurgitation peak velocity is an indirect measure of pulmonary  
235 artery systolic pressure. In spite of its flaws [23, 7], it is the most indicated method  
236 to date [19]. In this study, a positive correlation existed between CS diameter and  
237 tricuspid regurgitation peak velocity. In animals with early development of pulmonary  
238 hypertension, is frequently the absence of regurgitant jets [25, 22]. That being said,  
239 CS width might represent a surrogate for pulmonary artery systolic pressure in dogs  
240 at which tricuspid regurgitation is not properly identified and also complementary for  
241 diagnostic.

242 When absent from pathologies, the CS it is a venous structure that is difficult  
243 to perceive in the echocardiogram [15]. This study demonstrated that patients with  
244 low to higher degrees of PH have dilatation of this structure, which can be easily  
245 visualized. This is probably due to the dilation that occurs in the right atrium [5].  
246 Obtaining this measure has sensitivity and specificity, comparable to tricuspid  
247 regurgitation and was as good or better than TAPSE, FAC, AT/ET and RPAD and

248 the highest Likelihood ratio values, after tricuspid regurgitation, were from SC. This  
249 indicates that this is a significant predictor of PH, corroborating with Gunes et al [5].  
250 Thus, the CS is an index that can be added to the probabilistic assessment of PH in  
251 dogs and that it contributes to improving the accuracy of the routine examination, in  
252 agreement with the recommendation by Gunes et al (2008) [5]. However, the  
253 prevalence of dilated CS in patients with PH is still unknown and may be the subject  
254 of future investigations.

255           Regardless of the etiology of the disease, knowing aspects related to  
256 survival and prognosis is essential [16]. The ROC curves demonstrate that CS can  
257 be an excellent prognostic indicator, even in the short term. Other variables such as  
258 RPAD, TAPSE, AT/ET, FAC and PA/Ao were previously investigated and suggested  
259 as good prognostic indicators [18], which was not seen in this study. Recognizing  
260 the best echocardiographic variables associated with survival time in dogs is  
261 important to assist in clinical follow-up, treatment and certainly a better technical  
262 conduct and relationship with the owner. Furthermore, the association of different  
263 variables in the assessment of patients with PH leads more effectively to an  
264 assertive diagnosis [22]. In this study, CS proved to be efficient as a predictor of  
265 death from PH and therefore should be considered during the prognostic analysis  
266 of dogs.

267267

## 268 **LIMITATIONS**

269           This study should be interpreted having in mind its many limitations. Firstly,  
270 we lack a gold standard for determining pulmonary artery pressure, and diagnosis  
271 of PH was solely based on echocardiographic surrogates.

272           Although every effort was made to exclude cases which might present a  
273 dilated CS in the absence of PH (i.e. congenital right heart disease, pericardial  
274 effusion, degenerative tricuspid valve disease) we acknowledge that vascular

275 anomalies such as persistent left cranial vena cava were not completely ruled out  
276 by means of a microbubble study or computed tomography.

277           Although the CS measurements were indexed by weight, the heterogeneity  
278 of the group may be a limitation to be considered. In addition, studies with a larger  
279 number of dogs, with a specific dog breed group and followed for a larger period  
280 offer a good alternative for future investigations, especially for analysis of survival  
281 since few animals reached the final outcome.

282282

### 283 **CONCLUSIONS**

284           CS measurement can be performed at the beginning of the QRS and/or at  
285 the end of the T wave. Indexing is recommended, especially by aortic diameter and  
286 body surface area. The CS undergoes remodeling with probability of PH. CS  
287 measurement can be used to assess intermediate and high probability of PH and is  
288 positive correlated with tricuspid regurgitation. This measure has good sensitivity  
289 and specificity as a prognostic indicator, even better than other echocardiographic  
290 variables. in addition, it is a measure with good repeatability and reproducibility and  
291 is easy to obtain during the exam.

**292 REFERENCES**

- 293 [1] Amoozgar H, Fallahi M, Ajami G, Borzoei M. The Relationship of Coronary  
294 Sinus Dilation with Pulmonary Artery Pressure in Pediatric Patients. *Int Cardiovasc*  
295 *Res J* 2012; 6:56-61.
- 296 [2] Brecker SJ, Gibbs JS, Fox KM, Yacoub MH, Gibson DG. Comparison of Doppler  
297 derived haemodynamic variables and simultaneous high fidelity pressure  
298 measurements in severe pulmonary hypertension. *Heart* 1994; 72: 384-389.
- 299 [3] Cetin M, Cakici M, Zencir C, Tasolar H, Cil E, Yıldıř E, Ballı M, Abus S, Akturk  
300 E. Relationship between severity of pulmonary hypertension and coronary sinus  
301 diameter. *Rev Port Cardiol* 2015; 34: 329-335.
- 302 [4] Chan YH. Biostatistics 104: correlational analysis. *Singap Med J* 2003; 44: 614  
303 e 9.
- 304 [5] Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JÁ, Beghetti  
305 M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz  
306 C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis  
307 and treatment of pulmonary hypertension. *Eur Heart J* 2009; 30: 2493-2537.
- 308 [6] Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G,  
309 Peacock A, Noordegraaf AV, Beghetti M, Ghofrani A, Sanchez MAG, Hansmann G,  
310 Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT,  
311 Zompatori M, Hoeper M. Guidelines for the diagnosis and treatment of pulmonary  
312 hypertension: the joint task force for the diagnosis and treatment of pulmonary  
313 hypertension of the european society of cardiology (ESC) and the european  
314 respiratory society (ERS): endorsed by: association for european paediatric and  
315 congenital cardiology (AEPC), international society for heart and lung  
316 transplantation (ISHLT). *Eur Heart J* 2016; 37:67–119.
- 317 [7] Gall H, Yogeswaran A, Fuge J, Sommer N, Grimminger F, Seeger W, Olsson K  
318 M, Hoeper MM, Richter MJ, Tello K, Ghofrani HA. Validity of echocardiographic  
319 tricuspid regurgitation gradient to screen for new definition of pulmonary  
320 hypertension. *eClin Med* 2021; 34: 100822.
- 321 [8] Gunes Y, Guntekin U, Tuncer M, Kaya Y, Akyol A. Association of Coronary Sinus  
322 Diameter with Pulmonary Hypertension. *Echocardiogr* 2008; 25: 935-940.
- 323 [9] Isaacs D, Hazany S, Gamst A, Stark P, Mahmud E. Evaluation of the coronary  
324 sinus on chest computed tomography in patients with and without pulmonary artery  
325 hypertension. *J Comput Assist Tomogr* 2009; 33: 513-516.
- 326 [10] Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography  
327 for pulmonary hypertension: a systematic review and meta-analysis. *Heart* 2011;  
328 97: 612-622.
- 329 [11] Kellihan HB, Stepien RL. Pulmonary hypertension in canine degenerative mitral  
330 valve disease. *J Vet Cardiol* 2012; 14:149-164.
- 331 [12] Kellihan HB, Stepien RL. Pulmonary hypertension in dogs: diagnosis and  
332 therapy. *Vet Clin N Am: Small Animal Practice* 2010; 40: 623-641.



- 333 [13] Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation  
334 coefficients for reliability research. *J Chiropr Med* 2016; 15: 155 e 63.
- 335 [14] Lee MS, Shah AP, Dang N, Berman D, Forrester J, Shah PK, Aragon J, Jamal  
336 F, Makkar RR. Coronary sinus is dilated and outwardly displaced in patients with  
337 mitral regurgitation: quantitative angiographic analysis. *Catheter Cardiovasc Interv*  
338 2006; 67: 490-494.
- 339 [15] Mahmud E, Raisinghani A, Keramati S, Auger W, Blanchard DG, DeMaria AN.  
340 Dilatation of the coronary sinus on echocardiogram: prevalence and significance in  
341 patients with chronic pulmonary hypertension. *J Am Soc Echocardiogr* 2001; 14: 44-  
342 49.
- 343 [16] Morita T, Nakamura K, Osuga T, Takiguchi M. Incremental predictive value of  
344 echocardiographic indices of right ventricular function in the assessment of long-  
345 term prognosis in dogs with myxomatous mitral valve disease. *J Vet Cardiol* 2022;  
346 39: 51-62.
- 347 [17] Pyle RL, Abbott J, MacLean H. Pulmonary hypertension and cardiovascular  
348 sequelae in 54 dogs. *Int J Appl Res Vet Med*. 2004; 2:99–109.
- 349 [18] Raymond JR, Hinderliter AL, Willis PW, Ralph D, Caldwell E J, Williams W,  
350 Ettinger NA, Hill NS, Summer W R, Boisblanc B, Schwartz T, Koch G, Clayton L M,  
351 Jöbsis MM, Crow JW, Long W. Echocardiographic predictors of adverse outcomes  
352 in primary pulmonary hypertension. *J Am Coll Cardiol* 2002; 39: 1214-1219.
- 353 [19] Reiner C, Visser LC, Kellihan HB, Masseau I, Rozanski E, Clercx C, Williams  
354 K, Abbott J, Borgarelli M, Scansen BA. ACVIM consensus statement guidelines for  
355 the diagnosis, classification, treatment, and monitoring of pulmonary hypertension  
356 in dogs. *J Vet Intern Med* 2020; 34: 549-573.
- 357 [20] Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler  
358 Echocardiographic Estimates of Pulmonary Artery Pressures in Patients With  
359 Pulmonary Hypertension. *Chest* 2011; 139: 988-993.
- 360 [21] Serres FJ, Chetboul V, Tissier R, Sampedrano CC, Gouni V, Nicolle AP,  
361 Pouchelon J-L. Doppler echocardiography-derived evidence of pulmonary arterial  
362 hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005).  
363 *J Am Vet Med Assoc* 2006; 229:1772 – 1778.
- 364 [22] Soydan LC, Kellihan HB, Bates ML, Stepien RL, Consigny DW, Bellofiore A,  
365 Francois CJ, Chesler NC. Accuracy of Doppler echocardiographic estimates of  
366 pulmonary artery pressures in a canine model of pulmonary hypertension. *J Vet*  
367 *Cardiol* 2015; 17: 13-24.
- 368 [23] Studley J, Tighe DA, Joelson JM, Flack JE. The Hemodynamic Signs of  
369 Constrictive Pericarditis Can Be Mimicked by Tricuspid Regurgitation. *Cardiol Rev*  
370 2003;11: 320-326.
- 371 [24] Thomas WP, Gaber CE, Jacobs GJ, Kaplan PM, Lombard CW, Moise NS,  
372 Moses BL. Recommendations for Standards in Transthoracic Two-Dimensional  
373 Echocardiography in the Dog and Cat. *J Vet Intern Med* 1993; 7: 247-252.
- 374 [25] Venco L, Mihaylova L, Boon JA. Right Pulmonary Artery Distensibility Index  
375 (RPAD Index). A field study of an echocardiographic method to detect early

376 development of pulmonary hypertension and its severity even in the absence of  
377 regurgitant jets for Doppler evaluation in heartworm-infected dogs. *Vet Parasitol.*  
378 2014; 206:60–66.

379 [26] Waligóra M, Tyrka A, Miszalski-Jamka T, Urbańczyk-Zawadzka M, Podolec P,  
380 Kopec G. Right atrium enlargement predicts clinically significant supraventricular  
381 arrhythmia in patients with pulmonary arterial hypertension. *Heart & Lung* 2018;  
382 47:237-242.

383 [27] Yuce M, Davutoglu V, Yavuz S, Sari I, Kizilkan N, Ercan S, Akcay M, Akkoyun  
384 C, Dogan A, Alici H, Cavdar M, Buyukarslan H. Coronary sinus dilatation is  
385 associated with left ventricular systolic dysfunction and poor functional status in  
386 subjects with chronic heart failure. *Int J Cardiovasc Imaging* 2010; 26: 541-545.

387387

## FIGURAS






Figure 1 –Modified apical 4-chamber images used to measure the coronary sinus in dogs at the beginning of the QRS complex (A) and at the end of the T wave (B).



**Figure 2.** Survival analysis of dogs with varying degrees of PH according to measurement of CS.  ${}_aCS_T$ : average coronary sinus diameter measured at the end of the T wave;  ${}_aCS_{QRS}$ : average coronary sinus diameter measured at the beginning of the QRS complex;  $CS_{QRSB}$ : coronary sinus diameter measured at the beginning of the body surface area-indexed QRS complex;  $CS_{QRS_{Ao}}$ : coronary sinus diameter measured at the beginning of the aorta-indexed QRS complex;  $CS_{QRSR}$ : coronary sinus diameter measured at the beginning of the root of body weight-indexed;  $CS_{QRSW}$ : coronary sinus diameter measured at the beginning of the wheight-indexed;  $CS_{TB}$ : coronary sinus diameter measured at the end of the T wave, indexed by the body surface area;  $CS_{T_{Ao}}$ : coronary sinus diameter measured at the end of the T wave, indexed by aorta;  $CS_{TR}$ : coronary sinus diameter measured at the end of the T wave, indexed by root;  $CS_{TW}$ : coronary sinus diameter measured at the end of the T wave, indexed by wheight.



**Figure 3.** Survival analysis of dogs with varying degrees of PH according to echocardiographic variables. TR PV: tricuspid regurgitation peak velocity; TAPSE: tricuspid annular plane systolic excursion; FAC: fractional area change; PA/Ao: pulmonary artery -to- aorta ratio; AT/ET: pulmonary flow acceleration-to ejection time ratio; RPAD: Right pulmonary artery distensibility;.

## TABLES

**Table 1.** Echocardiographic variables used to evaluate the probability of PH in dogs. Data are presented as either mean±SD or median (IQR).

	Controls	PH <sub>i</sub>	PH <sub>i</sub>	PH <sub>h</sub>	p-value
FAC (%)	17±14.6	24.5±18	25.5±12	20,5±15.2	0.361
PA/Ao	0.93(-0.19)a	0.92(0.2)a	1.09(-0.25)c	1.26(-0.5)b	<0.001
ET (ms)	169(28.5)	156(34.5)	124(59.5)	123(45)	0.05
AT (ms)	75.3±30.5	69.9±30.9	68.9±21.4	66.1±25.9	0.051
AT/ET	0.5(0.2)	0.5(0.1)	0.5(0.2)	0.5(0.2)	0.606
RPAD %	28.7±9.6	25.9±11.2	25.1±9.3	27.6±9.5	0.742
TR PV (cm/s)	0(0)	256(39.6)c	284(72.5)a	436.8(77.2)b	<0.001
TR PG (mmHg)	.	26.5(8.25)c	40(19.5)a	74,0(26.75)b	<0.001

FAC: fractional area change; PA/Ao: pulmonary artery -to- aorta ratio; ET: pulmonary flow ejection time; AT: pulmonary flow acceleration time; AT/ET: pulmonary flow acceleration-to ejection time ratio; RPAD: Right pulmonary artery distensibility; TR PV: tricuspid regurgitation peak velocity; TR PG: tricuspid regurgitation pressure gradient.

**Table 2.** Measurements of the CS obtained at end-systole (end of the T wave) and end-diastole (beginning of the QRS complex) in healthy dogs and dogs with PH. Data are presented as either mean±SD or median (IQR).

	Control	PH <sub>i</sub>	PH <sub>i</sub>	PH <sub>h</sub>	p-value
<sup>a</sup> CS <sub>T</sub>	0.22±0.19 a	0.1 (0.13-0.21)a	0.36±0.25 b	0.56±0.26 c	<0.0001
CS <sub>TW</sub>	0.02±0.01 a	0.02±0.01 a	0.05±0.03 b	0.06(0.04-0.14) c	<0.0001
CS <sub>TR</sub>	0.09±0.05 a	0.08±0.02 a	0.17±0.09 b	0.28(0.15-0.37) c	<0.0001
CS <sub>TB</sub>	0.36±0.16 a	0.39±0.11 a	0.87±0.45 b	1.3(0.82-2.45) c	<0.0001
CS <sub>TA0</sub>	9.04(7.6-16.3) a	9.22±2.6 a	4.19(3.2-9.2) b	3.05±1.9 c	<0.0001
<sup>a</sup> CS <sub>QRS</sub>	0.23±0.17 a	0.15±0.06 a	0.25±0.15 b	0.42(0.29-0.7) c	0.0002
CS <sub>QRSW</sub>	0.02±0.01 a	0.016(0.01-0.02) a	0.03±0.01 b	0.05(0.03-0.1) c	<0.0001
CS <sub>QRSR</sub>	0.09±0.04 a	0.07±0.02 a	0.12±0.05 b	0.20(0.1-0.2) c	<0.0001
CS <sub>QRSB</sub>	0.38±0.15 a	0.35±0.1 a	0.6±0.2 b	1.04(0.6-1.4) c	<0.0001
CS <sub>QRSA0</sub>	8.45(6.5-10.7) a	10.5±1.7 a	6.9±3.6 b	3.6±1.7 c	<0.0001

<sup>a</sup>CS<sub>T</sub>: average coronary sinus diameter measured at the end of the T wave; CS<sub>TW</sub>:coronary sinus diameter measured at the end of the T wave, indexed by weight; CS<sub>TR</sub>: coronary sinus diameter measured at the end of the T wave, indexed by root; CS<sub>TB</sub>: coronary sinus diameter measured at the end of the T wave, indexed by the body surface area; CS<sub>TA0</sub>: coronary sinus diameter measured at the end of the T wave, indexed by aorta  
<sup>a</sup>CS<sub>QRS</sub>: average coronary sinus diameter measured at the beginning of the QRS complex; CS<sub>QRSW</sub>:coronary sinus diameter measured at the beginning of the weight-indexed; CS<sub>QRSR</sub>: coronary sinus diameter measured at the beginning of the root of body weight-indexed; CS<sub>QRSB</sub>: coronary sinus diameter measured at the beginning of the body surface area-indexed QRS complex; CS<sub>QRSA0</sub>: coronary sinus diameter measured at the beginning of the aorta-indexed QRS complex; IQR: interquartile range; SD: standard deviation.

**Table 3.** Correlations between echocardiographic variables and tricuspid regurgitation peak velocity.

	p-value	RHO
CS <sub>QRSB</sub>	<0.0001	0.7
CS <sub>TB</sub>	<0.0001	0.7
CS <sub>QRSR</sub>	<0.0001	0.6
CS <sub>TW</sub>	<0.0001	0.6
PA/Ao	<0.0001	0.6
CS <sub>TR</sub>	<0.0001	0.6
CS <sub>QRSW</sub>	<0.0001	0.5
aCS <sub>T</sub>	<0.0001	0.2
aCS <sub>QRS</sub>	<0.0001	0.2
ET	0.045	0.2
AT	0.055	0.1
TAPSE	0.267	-0.1
FAC	0.364	-0.3
RPAD	0.41	-0.6
AT/ET	0.689	-0.6
CS <sub>TAo</sub>	<0.0001	-0.7
CS <sub>QRSAo</sub>	<0.0001	-0.7

CS<sub>QRSB</sub>: coronary sinus diameter measured at the beginning of the body surface area-indexed QRS complex; CS<sub>TB</sub>: coronary sinus diameter measured at the end of the T wave, indexed by the body surface area; CS<sub>QRSR</sub>: coronary sinus diameter measured at the beginning of the root of body weight-indexed; CS<sub>TW</sub>: coronary sinus diameter measured at the end of the T wave, indexed by weight; PA/Ao: pulmonary artery-to-aorta ratio; CS<sub>TR</sub>: coronary sinus diameter measured at the end of the T wave, indexed by root; CS<sub>QRSW</sub>: coronary sinus diameter measured at the beginning of the weight-indexed; aCS<sub>T</sub>: average coronary sinus diameter measured at the end of the T wave; aCS<sub>QRS</sub>: average coronary sinus diameter measured at the beginning of the QRS complex; ET: pulmonary artery ejection time; AT: pulmonary artery acceleration time; TAPSE: tricuspid annular plane systolic excursion; FAC: fractional area variation; RPAD: right pulmonary artery distensibility; AT/ET: ratio pulmonary artery acceleration and ejection time; CS<sub>TAo</sub>: coronary sinus diameter measured at the end of the T wave, indexed by aorta; CS<sub>QRSAo</sub>: coronary sinus diameter measured at the beginning of the aorta-indexed QRS complex.



**Table 4.** Cut-off points, sensitivity and specificity of several echocardiographic variables used for identifying dogs with intermediate or high probability of PH.

	AUC	Cut-off	Sensitivity	95% CI	Specificity	95% CI	Likelihood ratio
TR PV	0.98	< 271.0	94.4	74.2% to 99.7%	95.6	79.0% to 99.8%	21.7
TR PG	0.97	< 30.0	93.3	70.2% to 99.7%	95.6	79.0% to 99.8%	21.5
CS <sub>TR</sub>	0.9	< 0.023	83.8	68.9% to 92.4%	87.0	67.9% to 95.5%	6.4
CS <sub>QRSB</sub>	0.9	< 0.48	83.8	68.9% to 92.4%	87.1	67.9% to 95.5%	6.4
CS <sub>TB</sub>	0.9	< 0.71	100	90.6% to 100.0%	78.4	58.1% to 90.4%	4.6
CS <sub>QRSW</sub>	0.9	< 0.02	72.3	57.0% to 84.6%	91.3	73.2% to 98.5%	8.4
PA/Ao	0.9	< 1.04	88.9	74.7% to 95.6%	78.3	58.1% to 90.4%	4.1
CS <sub>TAo</sub>	0.9	> 5.7	94.6	82.3% to 99.0%	82.6	62.9% to 93.0%	5.4
CS <sub>QRSR</sub>	0.9	< 0.12	91.9	78.7% to 97.2%	73.9	53.5% to 87.5%	3.5
aCS <sub>T</sub>	0.8	< 0.25	89.2	75.39% to 95.7%	82.6	62.9% to 93.0%	5.1
CS <sub>QRSAo</sub>	0.8	> 6.1	89.2	75.3% to 95.7%	78.3	58.1% to 90.3%	4.1
aCS <sub>QRS</sub>	0.8	< 0.24	78.4	62.8% to 88.6%	69.6	49.1% to 84.4%	2.6
CS <sub>TR</sub>	0.7	< 0.15	94.6	82.3% to 99.0%	82.6	62.9% to 93.0%	5.4
TAPSE	0.6	< 12.0	48.7	33.4% to 64.1%	78.3	58.1% to 90.3%	2.2
FAC	0.5	< 16.6	55.6	39.68% to 70.5%	72.7	51.9% to 86.9%	2.0
AT/ET	0.5	< 0.49	60	43.6% to 74.5%	54.6	34.7% to 73.1%	1.3
RPAD	0.5	> 12.80	100	90.1% to 100.0%	14.3	5% to 34.6%	1.2

TR PV: tricuspid regurgitation peak velocity; TR PG: tricuspid regurgitation pressure gradient; PA/Ao: pulmonary artery-to-aorta ratio;  $CS_{TW}$ : coronary sinus diameter measured at the end of the T wave, indexed by weight;  $CS_{QRSB}$ : coronary sinus diameter measured at the beginning of the body surface area-indexed QRS complex;  $CS_{TB}$ : coronary sinus diameter measured at the end of the T wave, indexed by the body surface area;  $CS_{QRSW}$ : coronary sinus diameter measured at the beginning of the weight-indexed; PA/Ao: pulmonary artery-to-aorta ratio;  $CS_{TAO}$ : coronary sinus diameter measured at the end of the T wave, indexed by aorta;  $CS_{QRSR}$ : coronary sinus diameter measured at the beginning of the root of body weight-indexed;  ${}_aCS_T$ : average coronary sinus diameter measured at the end of the T wave;  $CS_{QRSaO}$ : coronary sinus diameter measured at the beginning of the aorta-indexed QRS complex;  ${}_aCS_{QRS}$ : average coronary sinus diameter measured at the beginning of the QRS complex;  $CS_{TR}$ : coronary sinus diameter measured at the end of the T wave, indexed by root; TAPSE: tricuspid annular plane systolic excursion; FAC: fractional area variation; AT/ET: ratio pulmonary artery acceleration and ejection time; RPAD: right pulmonary artery distensibility.

**Table 5.** Cut-off points for echocardiographic variables with better specificity and sensitivity values to predict deaths from PH.

	AUC	Cut-off	Sensitivity	95% CI	Specificity	95% CI	Likelihood ratio
TR PV	0.9	> 306.0	100	72.3% to 100.0%	86	73.8% to 93.1%	7,1
CS <sub>QRSW</sub>	0.9	> 0.034	90	59.6% to 99.5%	84	71.5% to 91.7%	5,6
CS <sub>QRSAo</sub>	0.9	< 6.1	100	72.3% to 100.0%	76	62.6% to 85.7%	4,2
CS <sub>TAo</sub>	0.9	< 5.	100	72.3% to 100.0%	80	67% to 88.8%	5
PA/Ao	0.8	> 1.0	90	59.6% to 99.5%	74	60.5% to 84.1%	3,5
CS <sub>QRSB</sub>	0.7	> 0.36	90.6	71.1% to 98.3%	47,5	32.9% to 62.5%	1,7
CS <sub>TB</sub>	0.7	> 0.36	90.5	71.1% to 98.3%	52,5	37.5% to 67.1%	1,9
CS <sub>TW</sub>	0.7	> 0.02	85.7	65.4% to 95.0%	60	44.6% to 73.7%	2,1
CS <sub>TR</sub>	0.7	> 0.07	90.5	71.1% to 98.3%	47,5	32.9% to 62.5%	1,7
CS <sub>QRSR</sub>	0.7	> 0.11	71.4	50.0% to 86.2%	76	62.6% to 85.7%	3,0
FAC	0.6	> 17.4	88.9	56.5% to 99.4%	53,1	39.4% to 66.3%	1,9
RPAD	0.6	> 24.9	87.5	52.9% to 99.4%	45,8	32.6% to 59.7%	1,6
<sub>a</sub> CS <sub>T</sub>	0.6	> 0.27	52.4	32.4% to 71.7%	77,5	62.5% to 87.7%	2,3
AT/ET	0.6	< 0.53	88.9	56.5% to 99.4%	41,7	28.9% to 55.7%	1,5
<sub>a</sub> CS <sub>QRS</sub>	0.6	> 0.24	57.1	36.6% to 75.5%	67,5	52.0% to 79.9%	1,6
TAPSE	0.6	> 12.00	80	49.0% to 96.5%	42	29.4% to 55.8%	1,4

TR PV: tricuspid regurgitation peak velocity; CS<sub>QRSW</sub>: coronary sinus diameter measured at the beginning of the wheight-indexed; ; CS<sub>QRSAo</sub>: coronary sinus diameter measured at the beginning of the aorta-indexed QRS complex; CS<sub>TAo</sub>: coronary sinus diameter measured at the end of the T wave, indexed by aorta; PA/Ao: pulmonary artery-to-aorta ratio; CS<sub>QRSB</sub>: coronary sinus diameter measured at the beginning of the body surface area-indexed QRS complex; CS<sub>TB</sub>: coronary sinus diameter measured at the end of the T wave, indexed by the body surface area; CS<sub>TW</sub>: coronary sinus diameter measured at the end of the T wave, indexed by wheight; CS<sub>TR</sub>: coronary sinus diameter measured at the end of the T wave, indexed by root; CS<sub>QRSR</sub>: coronary sinus diameter measured at the beginning of the root of body weight-indexed; FAC: fractional

area variation; RPAD: right pulmonary artery distensibility;  $aCS_T$ : average coronary sinus diameter measured at the end of the T wave; AT/ET: ratio pulmonary artery acceleration and ejection time;  $aCS_{QRS}$ : average coronary sinus diameter measured at the beginning of the QRS complex; TAPSE: tricuspid annular plane systolic excursion.